ic14
mAbexperimentalCOVID-19
Clinical trial activity
15 trials · 11 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
12
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2002 (NCT00042588)
Timeline
Indications
Studied for
- Acute Lung Injury · Phase 2
- Amyotrophic Lateral Sclerosis · Phase 2
- Arrhythmogenic Right Ventricular Dysplasia · Phase 1/Phase 2
- Cardiomyopathies · Phase 1/Phase 2
- COVID-19 · Phase 2
- Dengue · Phase 2
- Heart Failure · Phase 1/Phase 2
- Lung Diseases · Phase 2
- Motor Neuron Disease · Phase 2
- Plakophilins · Phase 1/Phase 2
- Pneumonia · Phase 2
- Respiratory Distress Syndrome · Phase 2
- Sepsis · Phase 2
- ST Elevation Myocardial Infarction · Phase 1/Phase 2
- Stents · Phase 1/Phase 2
Mechanism of action
CD14 inhibitor
Diminishes inflammatory responses induced by i.v. injection of LPS.
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2109330 ↗
Also known as
- ic14
- ic14
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06513949 | Phase 2 | May 31, 2025 | Implicit Bioscience, University of Washington |
| NCT06678074 | Phase 1/Phase 2 (Phase 2) | Jan 3, 2025 | Implicit Bioscience, The Cleveland Clinic, Washington University in St. Louis |
| NCT06556810 | Phase 1/Phase 2 (Phase 2) | Oct 17, 2024 | Implicit Bioscience, University of Virginia, Virginia Commonwealth University |
| NCT06275893 | Phase 1/Phase 2 (Phase 2) | Mar 29, 2024 | Implicit Bioscience |
| NCT04390386 | Phase 2 | Dec 1, 2020 | — |
| NCT04391309 | Phase 2 | Jul 31, 2020 | Implicit Bioscience, University of Washington |
| NCT03875560 | Phase 2 | May 31, 2019 | Implicit Bioscience |
| NCT03474263 | Phase 2 | Sep 1, 2018 | Implicit Bioscience |
| NCT03508453 | Phase 2 | Aug 15, 2018 | Implicit Bioscience, Royal Brisbane & Women's Hospital |
| NCT03487263 | Phase 1 | Oct 1, 2017 | Implicit Bioscience, University of Queensland |
| NCT03017547 | Phase 2 | Jun 1, 2017 | Implicit Bioscience |
| NCT00233207 | Phase 2 | Sep 1, 2005 | National Heart, Lung, and Blood Institute (NHLBI), University of Washington |
| NCT00042588 | Phase 2 | May 1, 2002 | ICOS |
| NCT04346277 | N/A | — | Implicit Bioscience |
| NCT04309604 | N/A | — | Harvard University, Implicit Bioscience |
Showing 15 of 15 trials
Page 1 / 1
Organizations
Research & Development (11)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Implicit Bioscience | For profit | 12 | 12 | 3 | 2017 |
| University of Washington | Academic/Hospital | 3 | 1 | 1 | 2005 |
| Harvard University | Academic/Hospital | 1 | 0 | 1 | — |
| ICOS | For profit | 1 | 1 | 1 | 2002 |
| National Heart, Lung, and Blood Institute (NHLBI) | Government | 1 | 0 | 1 | 2005 |
| Royal Brisbane & Women's Hospital | Academic/Hospital | 1 | 0 | 1 | 2018 |
| The Cleveland Clinic | Academic/Hospital | 1 | 0 | 1 | 2025 |
| University of Queensland | Academic/Hospital | 1 | 0 | 1 | 2017 |
| University of Virginia | Academic/Hospital | 1 | 0 | 1 | 2024 |
| Virginia Commonwealth University | Academic/Hospital | 1 | 0 | 1 | 2024 |
| Washington University in St. Louis | Academic/Hospital | 1 | 0 | 1 | 2025 |
11 organizations
Page 1 / 1